Canaccord starts MapLight with Buy into schizophrenia data

Canaccord initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $35 price target The company is developing novel therapeutics for central nervous system disorders, the analyst tells investors in a research note. The firm views view MapLight as undervalued on the company’s schizophrenia opportunity alone. Canaccord tells investors to buy the stock into the Phase 2 data for ML-007C-MA in schizophrenia, expected in Q3.